All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The vector of anti-CEA chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human CEA. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-CEA antibody linked to CD28 and 41BB and CD3ζ signaling domains. And the vector product was designed for the treatment of CEA positive cancers.
CAR Construction : Fig.3 Reactivity of C2-45(cIgG1) with purified CEA in ELISA. After washing, the antibodies bound to CEA were detected with Huang, J., Shibaguchi, H., Zhao, J., Luo, N., Kuroki, M., Kinugasa, T., ... & Kuroki, M. (2006). IgG isotype conversion of a novel human anti-carcinoembryonic antigen antibody to increase its biological activity. Anticancer research, 26(2A), 1057-1063. |
CAR Construction : Fig.4 Reactivity of C2-45(cIgG1) with CEA-expressing cells in flow cytometric analysis. The cells used were incubated with C2-45(cIgG1),C2-45(IgG4) or control human IgG for 1 hour on ice. After washing, the cells were stained with fluorescein-conjugated rabbit anti-human IgG. Huang, J., Shibaguchi, H., Zhao, J., Luo, N., Kuroki, M., Kinugasa, T., ... & Kuroki, M. (2006). IgG isotype conversion of a novel human anti-carcinoembryonic antigen antibody to increase its biological activity. Anticancer research, 26(2A), 1057-1063. |
CAR Construction : Fig.5 Binding of C2-45(IgG1) with CEA-expressing cells in flow cytometric analysis. All measurements were performed in triplicate. Huang, J., Shibaguchi, H., Kuroki, M., Hirose, Y., Yamada, H., Zhao, J., ... & Kuroki, M. (2006). Subclass Conversion from IgG4 to IgG1 of a Novel Human Anti-CEA Antibody for Increasing Its Biological Activity. Japan Journal of Molecular Tumor Marker Research, 21, 53-54. |
CAR Construction : Fig.6 Specificity of anti-CEA mAb-mediated targeting. Transduction efficiency of CEACAM-transfected CHO cells evaluated by flow cytometry. Tanaka, T., Huang, J., Hirai, S., Kuroki, M., Kuroki, M., Watanabe, N., ... & Hamada, H. (2006). Carcinoembryonic Antigen–Targeted Selective Gene Therapy for Gastric Cancer through FZ33 Fiber-Modified Adenovirus Vectors. Clinical cancer research, 12(12), 3803-3813. |
CAR Construction : Fig.7 Competitive inhibition assay. CEA-CHO cells were transduced with Ax3CAZ3-FZ33 at 1,000 VP/cell after preincubation with C2-45. All measurements were performed in triplicate. Tanaka, T., Huang, J., Hirai, S., Kuroki, M., Kuroki, M., Watanabe, N., ... & Hamada, H. (2006). Carcinoembryonic Antigen–Targeted Selective Gene Therapy for Gastric Cancer through FZ33 Fiber-Modified Adenovirus Vectors. Clinical cancer research, 12(12), 3803-3813. |
CAR Construction : Fig.8 The L45scFv-CIR expression on human T-cells. Primary human T-cells (5x106 cells) were transfected with 2 Ìg of the L45scFv-CIR gene. Transfectants (1x106 cells) were stained with 1 Ìg/ml of APC-labeled BSA or CEA for 1 h at 4ÆC 24 hrs after nucleofection. Shibaguchi, H., Luo, N. X., Kuroki, M., Zhao, J., Huang, J., Hachimine, K., ... & Kuroki, M. (2006). A fully human chimeric immune receptor for retargeting T-cells to CEA-expressing tumor cells. Anticancer research, 26(6A), 4067-4072. |
CAR Construction : Fig.9 Binding of L45 scFv-CIR transfected primary human T-cells to CEA-expressing tumor cells. The CEA expressing MKN-45 cells were mixed with parental T-cells or transfectants at the ratio of 1:5 and incubated for rossette formation for 1 h at 37C. Shibaguchi, H., Luo, N. X., Kuroki, M., Zhao, J., Huang, J., Hachimine, K., ... & Kuroki, M. (2006). A fully human chimeric immune receptor for retargeting T-cells to CEA-expressing tumor cells. Anticancer research, 26(6A), 4067-4072. |
CAR Construction : Fig.10 The CEA binding activity of serially diluted 45scFvLCHα was evaluated by ELISA. Antigen binding activity of isolated 45scFvLCHα. Zhao, J., Kuroki, M., Shibaguchi, H., Wang, L., Huo, Q., Takami, N., ... & Kuroki, M. (2008). Recombinant human monoclonal igA antibody against CEA to recruit neutrophils to CEA-expressing cells. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics, 17(5), 217-222. |
CAR Construction : C2-45 scFv-28ζ Fig.1 The analysis of CAR protein expression. Lysates were prepared from wild-type and CAR-expressing Jurkat cells, and immunoreactive bands were detected by Western blotting using an anti-CD3ζ. Shirasu, N., Shibaguci, H., Kuroki, M., Yamada, H., & Kuroki, M. (2010). Construction and molecular characterization of human chimeric T-cell antigen receptors specific for carcinoembryonic antigen. Anticancer research, 30(7), 2731-2738. |
CAR Construction : C2-45 scFv-28ζ Fig.2 The formation of the signaling clusters in CAR-expressing cells by antigen stimulation. Jurkat cells co-expressing ZAP-70-AcGFP and CAR45-28ζ were plated onto a CEA-coated coverslips, fixed and stained with Alexa-labelled anti-CD3ζ and anti-myc antibodies. Shirasu, N., Shibaguci, H., Kuroki, M., Yamada, H., & Kuroki, M. (2010). Construction and molecular characterization of human chimeric T-cell antigen receptors specific for carcinoembryonic antigen. Anticancer research, 30(7), 2731-2738. |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-CEA (C2-45) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 (CAR-MZ172). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION